Navigation Links
New technology to speed up research into Huntington's disease

A new tool developed at Cambridge University represents a breakthrough in the race to find treatments to help sufferers with Huntington's disease.

Researchers have developed an effective new method of testing cognitive decline in mice with the disease, using an automated touch screen. It is hoped the screen will also allow researchers to study more effectively the cognitive difficulties in other neurodegenerative disorders such as in Alzheimer's and CJD.

Huntington's disease is a genetic disease affecting around 8 in 100,000 people. It is characterised by a progressive decline in cognitive functioning (including memory loss, intellectual decline and disorientation) together with the appearance of abnormal movements and impaired motor skills (such as unsteady gait and poor coordination).

There is currently no cure and whilst some symptoms can be alleviated, no treatments have been developed that help with cognitive deficits, a distressing aspect of the disease.

Whilst useful mouse models mimicking this disorder have been developed, it has been difficult to test cognitive skills such as learning, because most traditional experiments demand a level of physical performance that the mice cannot deliver due to the effect of the disease on their motor abilities.

The automated screen developed by Cambridge scientists provides a simple means of assessing cognition, in a way that requires minimal movement on the part of the mouse. The mouse makes its response by touching its nose to the touch-sensitive screen. This means that the HD mice can complete the task, despite motor problems.

Other benefits are that it is less labour intensive, less time consuming and less stressful for mice, compared to traditional testing methods. Given the difficulties associated with these traditional methods, progress to date in trialling new treatments for cognitive deficits has been slow with contract research organisations understan dably reluctant to engage with such research. Given the ease of use of the touch screen system, it is hoped this will change.

Dr Jenny Morton, Dr Lisa Saksida and Dr Tim Bussey from the Departments of Pharmacology and Experimental Psychology at the University of Cambridge, who led the research, tested normal mice and mice carrying the HD gene mutation. The task set was a choice between two visual stimuli on a touch-sensitive computer screen. If a mouse touched the correct stimulus, it was rewarded with food pellets; if it touched the incorrect stimulus, the lights went out and the mouse did not get a reward. Both normal and HD mice learnt to touch the correct stimulus with their noses and were able to learn the correct stimulus to obtain a reward by day 10.

The researchers also demonstrated that when the stimuli were reversed (so the stimulus that had previously been correct was now incorrect), HD mice struggled with the task although younger HD mice, who had not progressed as far in the disease, eventually learned it. When the mice were then presented with a new pair of stimuli, this proved too difficult even for the younger HD mice.

Importantly, and where the screen is so valuable, all the HD mice were physically able to complete the task (i.e. they were able physically to touch the screen and obtain rewards, even though their responses were often incorrect). This indicates that their poor cognitive performance was not secondary to motor impairments. It also confirms that mice with HD have cognitive problems that worsen with increasing age.

Dr Morton said, "We are very excited about the results from the touchscreen apparatus. For many HD patients, the cognitive and emotional symptoms are as disabling as the more obvious motor effects of the disease, and much effort is focused on understanding cognitive decline in HD".

"Useful cognitive testing has been a bottle-neck in developing new treatments for this aspect of HD. The touchscreen system should make it easier to test drugs for treating cognitive decline in HD."

It is hoped the touchscreen system will also be valuable for testing cognition in animals with other types of neurological dysfunction such as Alzheimer's disease or prion disease, and particularly where motor deficits make cognitive testing difficult or impractical. Dr Morton said "we are pleased at just how effective the test was and already clinical trial companies are showing an interest in the touch screen system".
'"/>

Source:University of Cambridge


Related biology news :

1. Novel technology detects human DNA mutations
2. Novel antiviral technology inhibits RSV infection in mice
3. The BIOS Initiative - open source biotechnology is born
4. Revolutionary nanotechnology illuminates brain cells at work
5. Study: homemade gene expression technology unreliable
6. First technology to remove prions that cause vCJD from blood launched
7. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
8. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
9. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
10. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
11. Vietnam war technology could aid elephant conservation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
Breaking Biology Technology: